About Morepen Laboratories Limited

Morepen Laboratories Limited is a public limited company incorporated and domiciled in India, listed on BSE and NSE. It manufactures, produces, develops, markets and distributes a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations, Over the Counter (OTC) products and Home Health products. Its manufacturing locations are in Himachal Pradesh, with trading and related activities across both domestic and global markets; the consolidated group comprises seven subsidiaries.

The company’s export footprint spans regulated and non-regulated markets and is supported by strong regulatory credentials, including USFDA-approved facilities at Masulkhana and Baddi, a PMDA (Japan) approval, and Anvisa Brazil approvals. In 2024-25, Morepen expanded into new export markets such as Thailand, Qatar and Oman.

Key Milestones of Morepen Laboratories Limited

Key milestones over its journey include: launch of the Diagnostic Division and an OTC brand; in-house manufacturing of gluco meters at Baddi; recognition of the Baddi R&D centre by the Government of India; USFDA approvals for Loratadine, Montelukast and Atorvastatin, among others; ISO 13485 certification for medical devices manufacturing by BSI, UK; a tie-up to manufacture the Sputnik vaccine in India; and the launch of the 360° weight management programme ‘LightLife’. The company also raised Global Depository Receipts in international markets and launched a CDMO business.

Business Verticals and Geographies of Morepen Laboratories Limited

Consolidated sales revenue mix: API 53.5%; Diagnostics 27.5%; Formulations 10%; OTC 9%. The company’s manufacturing locations are in Himachal Pradesh (Baddi, Parwanoo and Masulkhana), with trading and related activities across both domestic and global markets. The export footprint spans regulated and non-regulated markets including USFDA-approved facilities, PMDA (Japan) approval, and Anvisa Brazil approvals. In 2024-25, Morepen expanded into new export markets such as Thailand, Qatar and Oman.

Morepen Laboratories Limited Business Segment

Consolidated sales revenue mix: API 53.5%; Diagnostics 27.5%; Formulations 10%; OTC 9%. The company manufactures Active Pharmaceutical Ingredients (APIs), branded and generic formulations, Over the Counter (OTC) products and Home Health products. Manufacturing facilities are located in Baddi, Parwanoo and Masulkhana in Himachal Pradesh, serving both domestic and global markets.

Morepen Laboratories Limited Key Management

• Sushil Suri – Chairman & Managing Director
• Sanjay Suri – Whole-time Director
• Ajay Kumar Sharma – Chief Financial Officer
• Vipul Kumar Srivastava – Company Secretary

Latest Updates on Morepen Laboratories Limited

• Strategic portfolio actions: The company incorporated a new subsidiary in January 2025 with the strategic intent to hive off the medical devices business; a Business Transfer Agreement provides for transfer of the undertaking on a slump sale basis as a going concern.
• Capital raise: Morepen successfully raised Rs 20,000.00 Lakhs via a Qualified Institutions Placement (QIP), following members’ approval.
• API pipeline and filings: The company developed/commercialised Sitagliptin Hydrochloride, Finerenone, Cariprazine HCl, Resmetirom, Bempedoic Acid and Rupatadine Fumarate; filed US DMFs for Ticagrelor and Brexpiprazole; filed CEPs for Rosuvastatin calcium (Process 4) and Sitagliptin phosphate (Process 2); and submitted DMFs in China and multiple European countries for Vonoprazan, Linagliptin and Dapagliflozin variants. During the year, 1 patent was granted and 9 new patents were filed.
• Market positions: Export market shares strengthened in key APIs—Loratadine to 81%, Montelukast to 60%, Desloratadine to 30% and Fexofenadine to 25%; Atorvastatin’s export share improved to 19%.
• Devices and digital: The company launched the Dr. Morepen Sync App to help individuals monitor blood glucose, blood pressure and weight; it also advanced in-house screen printing, added a new manufacturing block under construction, started orthopaedics products manufacturing, and expanded its ISO certification scope to cover Blood Grouping Reagents and Lateral Flow Test Kits.
• OTC innovation and channel reach: The OTC vertical introduced ‘LightLife’, a 360° weight management programme, and broadened distribution with national and regional retail chains, including the Indian Army’s Eastern and Northern Commands and prominent outlets like Apollo Pharmacy.
• Overseas expansion: Post year-end, the company incorporated a wholly owned subsidiary in Dubai Silicon Oasis on June 18, 2025, to expand overseas reach for the API business, and a step-down subsidiary in Dubai for medical equipment trading.